Slowing Growth of Watchman and Shifting Trends in Atrial Fibrillation Combination Procedures

Boston Scientific's left atrial appendage closure (LAAC) device, Watchman, is experiencing significant growth stagnation in the U.S. market. The revenue growth rate, which was close to 30% in 2025, plummeted to 4.2% in the second quarter of 2026, resulting in quarterly revenue of $507 million. This is because physicians are increasingly preferring combination procedures (concomitant procedure) that simultaneously address other cardiac conditions, such as atrial fibrillation ablation, rather than standalone LAAC procedures for stroke prevention, which has significantly altered existing patient referral patterns. As a result, the volume of standalone LAAC procedures has fallen to the low teens, signaling a crack in the dominance of Boston Scientific's core cash cow in the global LAAC market, which is approximately $1.9 billion annually in 2025-2026.

Loss of First-Mover Advantage for Farapulse PFA System and Entry of Strong Competitors

The Farapulse PFA System, which led the pulsed field ablation (PFA) market, has also seen its market share rapidly decline to approximately 41% due to aggressive competition from other companies. In the global PFA market, which is experiencing explosive growth of approximately $2 billion in 2026, Medtronic's PulseSelect PFA, Johnson & Johnson's Varipulse PFA, and Abbott's Volt PFA have all completed FDA approval and are actively entering the market. Although it initially enjoyed a monopoly due to its innovative safety in isolating the pulmonary veins through non-thermal electroporation, the entry of latecomers has increased the cost burden of defending market share. As the temporary effect of the new product launch fades, creating synergies with diversified devices and 3D mapping systems has become a key to survival.

Repeated Guidance Cuts Impact Investment Confidence

With the simultaneous slowdown in growth of the electrophysiology and LAAC business units, which were the company's main growth engines, Boston Scientific has lowered its annual earnings guidance for the second consecutive quarter. The company lowered its 2026 annual organic revenue growth guidance from 6.5% to 8% to 5% to 6%, and its adjusted EPS guidance from $3.34 to $3.41 to $3.28 to $3.32. CEO Michael Mahoney has warned that the market pressure will continue for an extended period until 2027. This earnings guidance revision is not just a reflection of a weak quarterly performance, but also raises doubts about the sustainability of Boston Scientific's long-term growth model, leading to investor outflows and increased stock price volatility.

Launch of Aggressive Global Restructuring to Secure Reinvestment Funds

To address the performance pressure, Boston Scientific has launched an emergency global restructuring program in 2026, focusing on supply chain optimization, organizational streamlining, and indirect cost reduction. This restructuring, which will continue until the end of 2029, is expected to result in temporary costs of $700 million to $800 million on a pre-tax basis, but will save approximately $500 million in pre-tax operating expenses annually after completion. Although there are risks of disruption in some business units due to layoffs and organizational restructuring, the company's strong commitment to reinvesting the secured surplus funds in next-generation portfolios, which will be the future growth drivers, is evident. Boston Scientific is implementing its plan to control inefficient spending proactively, overcome the performance low, and demonstrate a meaningful turnaround from 2028.